Objective. To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Design. Prospective 36 months cohort study of patients switched to zidovudine/stavudine plus didanosine plus lopinavir/ritonavir capsules as second-line regimen. Methodology. Structured interview, medical examination, and laboratory assessment performed every 6 months. Results. We enrolled 40 patients; 1 died and 3 were lost to follow-up. Median CD4+ count at baseline was 108 cell/μL, median log viral load was 4.8 copies/mL. Sixteen (40%) patients had baseline genotypic resistant test, 14 (87%) had lamivudine resistance mutations, and all had NNRTIs resistance mutations. At month 36, 82% of the patients achieved viral suppression (<400 copies/ mL) and the median increase in CD4+ count was 214 cell/μL, (interquartile range: 128-295). Twenty-five patients (62%) experienced at least one adverse event. Conclusions. Our study confirms lopinavir/ ritonavir-based second-line regimen but with a high rate of toxicities.
Towards universal access: AIDS report.Scaling up priority HIV/AIDS interventions in the health sector: progress report 2008 . Geneva: WHO, UNAIDS, UNICEF. Available at: http//www.who.int/hiv/mediacentre/2008progressreport/en/index.html . Accessed August 10, 2008.
2.
Pujades-Rodríguez M., O'Brien D., Humblet P., Calmy A.Second-line antiretroviral therapy in resource-limited settings: the experience of Médecines Sans Frontières . AIDS . 2008;22:1305-1312.
3.
WHO.Global price reporting mechanism . Available at: http://www.who.int/hiv/amds/price/hdd/index.aspx . Accessed 20, August 2008.
4.
Consultation on Technical and Operational Recommendations for Scale-up of Laboratory Services and Monitoring HIV Antiretroviral Therapy in Resource-limited Settings. Geneva: World Health Organization ; 2006.
5.
WHO.Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Geneva: WHO; 2006. Available at: http://www.who.int/hiv/pub/guidelines/art/en/index.html . Accessed May 5, 2008.
6.
Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., Chantratita1 W. Options for a second-line antiretroviral regimen for HIV Type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007 ;44:447-452.
7.
Renaud-Thery F., Nguimfack BD, Vitoria M., et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens . AIDS. 2007 ;21(suppl 4):S89-S95.
8.
1st ed National Antiretroviral treatment and Care Guidelines for Adults and Children. Republic of Uganda , Uganda: Ministry of health ; 2003.
9.
Spacek L., Shibab H., Kamya M., et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42:252-259.
10.
Arribas J., Pulido F., Delgado R., et al. Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, proof of concept pilot clinical trial (OK04 Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
11.
Campo RE, Lalanne R., Tanner T., et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005;19:447-449.
12.
Pateson D., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
13.
McNabb J., Ross JW, Abriola K., Turley C., Nightingale CH, Nicolau DPAdherence to highly active antiretroviral therapy predict virologic outcome at an inner-city immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
14.
Oyugi JH, Byakika-Tusiime J., Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting . J Acquir Immune Defic Syndr. 2004;36:1100-1102.
15.
Kiguba R., Byakika-Tusiime J., Karamagi C., Ssali F., Mugyenyi P., Katabira E.Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr. 2007;45:218-223.
16.
Forna F., Liechty CA, Solberg P., et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44:456-462.
17.
Songa PM, Castelnuovo B., Mugasha EB, Ocama P., Kambugu A.Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis. 2007;45:514-517.
18.
Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr . 2007;46:318-322.
19.
Rosen S., Long L., Fox M., Sanne I.Cost and cost-effectiveness of switching from stavudine to tenofovir in first line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008;48:334-343.
20.
Gupta RK, Hill A., Sawyer W., Pillay D.Drug resistance after virological failure on first-line HAART in resource rich and poor settings: a meta-analysis. XV Conference Presented at CROI 2008; February 3-6, 2008; Boston, MA. Abstract 891.
